A CD2/CD28 chimeric receptor triggers the CD28 signaling pathway in CTLL.2 cells

Gene Therapy

Volumn 4, Issue 8, 1997, Pages 833-838

  Feldhaus, A L ^a   Evans, L ^a   Sutherland, R A ^a   Jones, L A ^a  

^a Targeted Genetics Corporation   (United States)

Author keywords

Adoptive immunotherapy; CD2; CD28; Costimulation

Indexed keywords

CD2 ANTIGEN; CD28 ANTIGEN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; T LYMPHOCYTE RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL CELL; ARTICLE; CELL LINE; CELL PROLIFERATION; CELL SURFACE; CHIMERA; CONTROLLED STUDY; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN DOMAIN; RETROVIRUS; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANIMALIA; UNIDENTIFIED RETROVIRUS;

EID: 0030847770     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300456     Document Type: Article

References (41)

1. Riddell SR, Greenberg PD. Principles for adoptive T cell therapy of human viral diseases. Annu Rev Immunol 1995; 13: 545-586.
2. Rosenberg SA. Karnofsky memorial lecture. The immunotherapy and gene therapy of cancer. J Clin Oncol 1992; 10: 180-199.
3. Dalgleish AG. The role of IL-2 in gene therapy. Gene Therapy 1994; 1: 83-87.
4. Schwarte RH, Mueller DL, Jenkins MK, Quill H. T-cell clonal anergy. Cold Spring Harb Symp Quant Biol 1989; 54: 605-610.
5. Jenkins MK. The role of cell division in the induction of clonal anergy. Immunol Today 1992; 13: 69-73.
6. Bretscher P The two-signal model of lymphocyte activation twenty-one years later. Immunol Today 1992; 13: 74-76.
7. Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 1993; 11: 191-212.
8. Allison JP. CD28-B7 interactions in T-cell activation. Curr Opin Immunol 1994, 6: 414-419
9. Guinan EC et al. Pivotal role of the B7.CD28 pathway in transplantation tolerance and tumor immunity. Blood 1994; 84: 3261-3282.
10. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu RET Immunol 1996; 14: 233-258.
11. Boise LH et al. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity 1995; 3: 87-98.
12. Viola A, Lanzavecchia A. T cell activation determined by T cell receptor number and tunable thresholds. Science 1996; 273: 104-106.
13. Cai Z, Sprent J. Influence of antigen dose and coslimulation on the primary response of CD8′ T cells in vitro. J Exp Med 1996; 183: 2247-2257.
14. Henderson RA, Finn OJ. Human tumor antigens are ready to fly. Adv Immunol 1996; 62: 217-256.
15. Ostrand-Rosenberg S. Tumor immunotherapy: the tumor cell as an antigen-presenting cell. Curr Opin Immunol 1994; 6: 722-727.
16. Roth C, Rochlitz C, Kourilsky P. Immune responses against tumors. Adv Immunol 1994; 57: 281-351.
17. Freeman GJ et al. B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J Immunol 1989; 143: 2714-2722.
18. Freeman GJ et al. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 1993; 262: 909-911.
19. Azuma M et al. B70 antigen is a second ligand for CTLA-4 and CD28. Nature 1993; 366: 76-79.
20. + T cells by B7-transfected melanoma cells. Science 1993; 259: 368-370.
21. Chen L, Linsley PS, Hellstrom KE. Costimulation of T cells for tumor immunity. Immunol Today 1993; 14: 483-486.
22. Bierer BH, Barbosa J, Herrmann S, Burakoff SJ. Interaction of CD2 with its ligand, LFA-3, in human T cell proliferation. J Immunol 1988; 140: 3358-3363.
23. Kresky AM et al. The functional significance, distribution, and structure of LFA-1, LFA-2, and LFA-3: cell surface antigens associated with CTL-target interactions. J Immunol 1983; 131: 611-616.
24. Gillis S, Smith KA Long term culture of tumour specific cytotoxic T cells. Nature 1977; 268: 154-156.
25. Davis SJ, van der Merwe PA. The structure and ligand interactions of CD2: implications for T-cell function. Immunol Today 1996; 17: 177-187.
26. Fry MJ, Waterfield MD. Structure and function of phosphatidyl-inositol 3-kinase: a potential second messenger system involved in growth control. Philos Trans R Soc Lond B Biol Sci 1993; 340: 337-344.
27. Prasad KVS et al. T-cell antigen CD28 interacts with the lipid kinase phosphatidylinositol 3-kinase by a cytoplasmic Tyr(P)-Met-Xaa-Met motif. Proc Natl Acad Sci USA 1994; 91: 2834-2838.
28. 2+-independent costimulatory activity. Eur J Immunol 1994; 24: 2732-2739.
29. Umlauf SW et al. Molecular regulation of the 1L-2 gene: rheostatic control of the immune system. Immunol Rev 1993; 133: 177-197.
30. Damle NK, Klussman K, Linsley PS, Aruffo A. Differential costimulatory effects of adhesion molecules B7, ICAM-1, LFA3, and VCAM-1 on resting and antigen-primed CD4+ T lymphocytes. J Immunol 1992; 148: 1985-1992.
31. Damle NK et al. Differential regulatory effects of intercellular adhesion molecule-1 on costimulation by the CD28 counter-receptor B7. J Immunol 1992; 149: 2541-2548.
32. 2+ levels. J Immunol 1992; 149: 3872-3880.
33. Van Gool SW, de Boer M, Creuppens JL. CD28 ligation by monoclonal antibodies or B7/BB1 provides an accessory signal for the cyclosporin A-resistant generation of cytotoxic T cell activity. J Immunol 1993; 150: 3254-3263.
34. Pierres A et al. Triggering CD28 molecules synergize with CD2 (T11.1 and T11.2)-mediated T cell activation. Eur J Immunol 1988; 18: 685-690.
35. Van Lier RAW, Brouwer M, Aarden LA. Signals involved in T cell activation. T cell proliferation induced through the synergistic action of anti-CD28 and anti-CD2 monoclonal antibodies. Eur J Immunol 1988; 18: 167-172.
36. Li Y, Hellstrom KE, Newby SA, Chen L. Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors. J Exp Med 1996; 183: 639-644.
37. Mann R, Mulligan RC, Baltimore D. Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell 1983; 33: 153-159.
38. Miller AD, Buttimore C. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol Cell Biol 1986; 6: 2895-2902.
39. Seed B, Aroffo A. Molecular cloning of the CD2 antigen, the T-cell erythrocyte receptor, by a rapid immunoselection procedure. Proc Natl Acad Sci USA 1987; 84: 3365-3369.
40. Aruffo A, Seed B. Molecular cloning of a CD28cDNA by a high-efficiency COS cell expression system. Proc Natl Acad Sci USA 1987; 84: 8573-8577.
41. Lupton SD, Brunton LL, Kalberg VA, Overell RW. Dominant positive and negative selection using a hygromycin phosphotransferase-thymidine kinase fusion gene. Mol Cell Biol 1991; 11: 3374-3378.